Alira Health

Alira HealthAlira Health
Alira Health

Alira Health

Global healthcare advisory and clinical research firm providing patient-centric, technology-enabled solutions for life sciences.

DR 471999InactiveFramingham, United States
Rate

About

Alira Health is a global life sciences advisory and CRO that humanizes healthcare by integrating consulting, CRO services, and technology platforms. They serve life sciences companies, offering expertise in research and clinical development, regulatory affairs, and market access. Alira Health focuses on accelerating life sciences research and improving patient outcomes through a blend of empathy and scientific rigor.
Frequently asked

What does Alira Health do?

Alira Health is a global life sciences advisory and CRO that humanizes healthcare by integrating consulting, CRO services, and technology platforms. They serve life sciences companies, offering expertise in research and clinical development, regulatory affairs, and market access. Alira Health focuses on accelerating life sciences research and improving patient outcomes through a blend of empathy and scientific rigor.

What is Alira Health's revenue?

StartupHub estimates Alira Health's annual revenue at $72.8M (range $14.0M to $112.0M, 32% confidence), based on comparable companies in the sector.

What is Alira Health's valuation?

StartupHub estimates Alira Health's effective valuation at $932.0M (range $582.5M to $1.4B, 17% confidence), based on comparable companies in the sector.

How much funding has Alira Health raised?

Alira Health has raised a total of $233M in funding. The most recent round on record is Bridge.

Where is Alira Health headquartered?

Alira Health is headquartered in Framingham, United States.

When was Alira Health founded?

Alira Health was founded in 1999.

What industry does Alira Health operate in?

Alira Health operates in Healthcare, Life Sciences, Biotech, HealthTech, Clinical Research.

What is Alira Health's current status?

Alira Health's current operating status is: Inactive.

Comments

No comments yet. Be the first to share your take.